Literature DB >> 22360379

Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity.

Chiung-Zuei Chen1, Chih-Ying Ou, Wen-Ling Wang, Cheng-Hung Lee, Chien-Chung Lin, Han-Yu Chang, Tzuen-Ren Hsiue.   

Abstract

BACKGROUND: The current standards for the diagnosis and treatment of patients with COPD clearly rely on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria based on post-bronchodilator spirometric values. However, clinical evidence for using the post-bronchodilator FEV₁ in the severity classification has not been fully investigated.
METHODS: Patients with COPD were enrolled and followed up prospectively between October 2006 and January 2011. We compared the observed 3-year risk of all causes and respiratory mortality with the risk predicted by the pre- and post-bronchodilator percent predicted FEV₁. Other important phenotypes including BMI, MMRC dyspnea scale, ECOG performance status and severe AECOPD (acute exacerbation) were also compared between the two groups. The different severity classifications of COPD, measured according the GOLD guidelines by post- and pre-bronchodilator percent predicted FEV₁ were compared for prediction of mortality.
RESULTS: There were 35 deaths among the 300 COPD patients (11.7%). Multivariate analysis showed that the post-bronchodilator percent predicted FEV₁ was a significant independent predictor of mortality but pre-bronchodilator percent predicted FEV₁ was not (p = 0.008 vs 0.126) and it was more strongly correlated with all studied predictors of outcome than the pre-bronchodilator percent predicted FEV₁. Kaplan-Meier analysis showed that the discrimination ability to predict mortality from the GOLD criteria using post bronchodilator percent predicted FEV₁ (p = 0.009) was better than using pre-bronchodilator percent predicted FEV₁ (p = 0.131).
CONCLUSIONS: The post-bronchodilator percent predicted FEV1 is better than the pre-bronchodilator percent predicted FEV₁ in the evaluation of the severity of disease in COPD patients and is more accurate in predicting the risk of death by the GOLD classification.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360379     DOI: 10.3109/15412555.2012.654529

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  10 in total

1.  Using Demographic Factors and Comorbidities to Develop a Predictive Model for ICU Mortality in Patients with Acute Exacerbation COPD.

Authors:  Sukrit S Jain; Indra Neil Sarkar; Paul C Stey; Rajsavi S Anand; Dustin R Biron; Elizabeth S Chen
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

2.  Admixture mapping identifies a quantitative trait locus associated with FEV1/FVC in the COPDGene Study.

Authors:  Margaret M Parker; Marilyn G Foreman; Haley J Abel; Rasika A Mathias; Jacqueline B Hetmanski; James D Crapo; Edwin K Silverman; Terri H Beaty
Journal:  Genet Epidemiol       Date:  2014-08-11       Impact factor: 2.135

Review 3.  Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC.

Authors:  Daniel Hoesterey; Nilakash Das; Wim Janssens; Russell G Buhr; Fernando J Martinez; Christopher B Cooper; Donald P Tashkin; Igor Barjaktarevic
Journal:  Respir Med       Date:  2019-08-09       Impact factor: 3.415

4.  Using cluster analysis to identify phenotypes and validation of mortality in men with COPD.

Authors:  Chiung-Zuei Chen; Liang-Yi Wang; Chih-Ying Ou; Cheng-Hung Lee; Chien-Chung Lin; Tzuen-Ren Hsiue
Journal:  Lung       Date:  2014-10-07       Impact factor: 2.584

5.  Paranasal sinus opacification at MRI in lower airway disease (the HUNT study-MRI).

Authors:  Aleksander Grande Hansen; Anne-Sofie Helvik; Wenche Moe Thorstensen; Ståle Nordgård; Arnulf Langhammer; Vegard Bugten; Lars Jacob Stovner; Heidi Beate Eggesbø
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-26       Impact factor: 2.503

6.  Conflicting role of sarcopenia and obesity in male patients with chronic obstructive pulmonary disease: Korean National Health and Nutrition Examination Survey.

Authors:  Hyeon-Kyoung Koo; Joo-Hyun Park; Hye Kyeong Park; Hoon Jung; Sung-Soon Lee
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

7.  Association of incidental emphysema with annual lung function decline and future development of airflow limitation.

Authors:  Hyeon-Kyoung Koo; Kwang Nam Jin; Deog Kyeom Kim; Hee Soon Chung; Chang-Hoon Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-01-29

8.  Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes.

Authors:  Spyridon Fortis; Michael Eberlein; Dimitris Georgopoulos; Alejandro P Comellas
Journal:  BMJ Open Respir Res       Date:  2017-12-18

9.  Validation of the GOLD 2017 and new 16 subgroups (1A-4D) classifications in predicting exacerbation and mortality in COPD patients.

Authors:  Meng-Zhi Han; Tzuen-Ren Hsiue; Sheng-Han Tsai; Tang-Hsiu Huang; Xin-Min Liao; Chiung-Zuei Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-18

10.  Development and validation of a prediction index for recent mortality in advanced COPD patients.

Authors:  Tzuen-Ren Hsiue; Chiung-Zuei Chen; Sheng-Han Tsai; Chia-Yin Shih; Chin-Wei Kuo; Xin-Min Liao; Peng-Chan Lin; Chian-Wei Chen
Journal:  NPJ Prim Care Respir Med       Date:  2022-01-13       Impact factor: 2.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.